{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:05:40Z","timestamp":1784966740588,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jbspin.2013.12.002","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T02:46:50Z","timestamp":1389322010000},"page":"6-14","source":"Crossref","is-referenced-by-count":85,"title":["Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis"],"prefix":"10.1016","volume":"81","author":[{"given":"Daniel","family":"Wendling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Claudepierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2013.12.002_bib0005","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0010","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0015","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0025","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/rheumatology\/kes066","article-title":"First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"51","author":"van den Berg","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0030","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","article-title":"Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis","volume":"51","author":"Baraliakos","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0045","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jbspin.2007.10.003","article-title":"Recommendations of the French society for rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update","volume":"74","author":"Pham","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1297-319X(11)70001-X","article-title":"TNF alpha antagonist therapy and safety monitoring","volume":"78","author":"Pham","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0060","article-title":"Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis","author":"Schoels","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0075","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jbspin.2012.06.003","article-title":"Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?","volume":"79","author":"Claudepierre","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0085","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jbspin.2012.06.009","article-title":"Non-radiographic spondyloarthritis: a theoretical concept or a real entity?","volume":"79","author":"Wendling","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0090","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jbspin.2013.04.010","article-title":"Overdiagnosing early spondyloarthritis: what are the risks?","volume":"80","author":"Berthelot","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0095","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/ard.2009.110767","article-title":"Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0100","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jbspin.2011.02.012","article-title":"Mortality in spondylarthritis","volume":"78","author":"Prati","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0105","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.100686","article-title":"Work disability in patients with ankylosing spondylitis in Norway","volume":"38","author":"Bakland","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jbspin.2013.03.003","article-title":"Early diagnosis and management are crucial in spondyloarthritis","volume":"80","author":"Wendling","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/eci.13.35","article-title":"Spondyloarthritis and smoking: towards a new insight into the disease","volume":"9","author":"Wendling","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jbspin.2011.06.005","article-title":"On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study","volume":"79","author":"Sudre","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1756-0500-6-185","article-title":"Short-term in patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice","volume":"6","author":"Eppeland","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0140","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2340\/16501977-1078","article-title":"A three-week multidisciplinary in patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial","volume":"45","author":"Kjeken","year":"2013","journal-title":"Rehabil Med"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00296-011-2147-9","article-title":"The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF-inhibitors","volume":"33","author":"Ciprian","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-011-1791-5","article-title":"Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions","volume":"31","author":"Aytekin","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0155","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00296-011-1932-9","article-title":"Effect of pilates training on people with ankylosing spondylitis","volume":"32","author":"Altan","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0160","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2340\/16501977-0804","article-title":"Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting","volume":"43","author":"Staalesen Strumse","year":"2011","journal-title":"J Rehabil Med"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0165","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3899\/jrheum.100987","article-title":"Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial","volume":"38","author":"Masiero","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0170","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.rdc.2012.08.010","article-title":"Co-morbidities in patients with spondyloarthritis","volume":"38","author":"van der Horst-Bruinsma","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0175","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10067-012-2018-0","article-title":"High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review","volume":"31","author":"van der Weijden","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0180","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3899\/jrheum.120316","article-title":"Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton","volume":"39","author":"Klingberg","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3899\/jrheum.120240","article-title":"Osteoporosis and psoriatic arthritis","volume":"89","author":"Del Puente","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0190","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/ar3833","article-title":"Osteoporosis in ankylosing spondylitis -prevalence, risk factors and methods of assessment","volume":"14","author":"Klingberg","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0195","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","article-title":"Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis","volume":"49","author":"Escalas","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0200","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/rheumatology\/kep393","article-title":"Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs\/coxibs\u2019 treatment effect on C-reactive protein","volume":"49","author":"Benhamou","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0205","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jbspin.2013.06.003","article-title":"Do non-steroidal anti-inflammatory drugs have disease-modifying effects in spondyloarthritis?","volume":"80","author":"Wendling","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0210","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0215","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","author":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0220","first-page":"CD008886","article-title":"Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)","author":"Ramiro","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0225","first-page":"642","article-title":"Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis","volume":"29","author":"Huang","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0230","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.2237","article-title":"Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial","author":"Haibel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0410","first-page":"CD004524","article-title":"Methotrexate for ankylosing spondylitis","volume":"2","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0385","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0390","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0415","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3899\/jrheum.110885","article-title":"Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement","volume":"39","author":"Braun","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0235","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0240","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/rheumatology\/kes059","article-title":"Methotrexate in peripheral spondyloarthritis including psoriatic arthritis: a need for further evaluation","volume":"51","author":"Dougados","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0245","first-page":"574","article-title":"Conseils d\u2019utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellis\u00e9es par la Haute Autorit\u00e9 de sant\u00e9 fran\u00e7aise","volume":"80","author":"Goeb","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0250","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/BOR.0b013e32835257c5","article-title":"Baseline predictors of response to TNF-\u03b1 blocking therapy in ankylosing spondylitis","volume":"24","author":"Arends","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0255","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3841","article-title":"Body mass index influences the response to infliximab in ankylosing spondylitis","volume":"14","author":"Ottaviani","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0260","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0265","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","article-title":"Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis","volume":"33","author":"Machado","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0270","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1136\/ard.2009.121533","article-title":"A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial","volume":"69","author":"Dougados","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0275","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/rheumatology\/kes125","article-title":"Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study","volume":"51","author":"Dougados","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0280","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar3350","article-title":"Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study","volume":"13","author":"Mulleman","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0290","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","article-title":"Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab","volume":"71","author":"Plasencia","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0295","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0400","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor (inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0420","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double-blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0305","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/ker083","article-title":"High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double-blind, controlled multicentre study (LOADET study)","volume":"50","author":"Navarro-Sarabia","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jbspin.2011.11.004","article-title":"Should anti-TNF-\u03b1 drug levels and\/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?","volume":"79","author":"Mulleman","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0315","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0320","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","article-title":"Efficacy in current practice of switching between anti-tumour necrosis factor-\u03b1 agents in spondyloarthropathies","volume":"50","author":"Paccou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0300","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0325","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","article-title":"Dosage adjustment of anti-tumor necrosis factor-\u03b1 inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice","volume":"39","author":"Paccou","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0330","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Comp\u00e1n","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0335","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jbspin.2011.02.013","article-title":"Optimizing TNF\u03b1 antagonist therapy in patients with spondyloarthritis: why and how?","volume":"78","author":"Wendling","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14728214.2013.749857","article-title":"Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?","volume":"18","author":"Wendling","year":"2013","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0345","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0350","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0355","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/annrheumdis-2012-201926","article-title":"One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0360","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3899\/jrheum.120201","article-title":"Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology","volume":"39","author":"Wendling","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0365","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3766","article-title":"Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study","volume":"14","author":"Lekpa","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0370","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0405","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0375","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","author":"McInnes","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0425","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0380","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0430","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2013.12.002_bib0395","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/BOR.0b013e3283620e04","article-title":"Hip disease in ankylosing spondylitis","volume":"25","author":"Vander Cruyssen","year":"2013","journal-title":"Curr Opin Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X13002881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X13002881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T23:49:37Z","timestamp":1716421777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X13002881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1297319X13002881"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2013.12.002","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}